Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Liver Neoplasms

abstract

  • The addition of Bev to adjuvant HAI plus systemic therapy after liver resection did not seem to increase RFS or survival but appeared to increase biliary toxicity. Four-year survival was 85% and 81% for no Bev and Bev arms, respectively.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3646323

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.5977

PubMed ID

  • 21189384

Additional Document Info

start page

  • 884

end page

  • 9

volume

  • 29

number

  • 7